July 21, 2020 – Acentrus Specialty (Irving, TX), a national network of health systems and hospitals providing specialty pharmacy care for their patients, has agreed with Puma Biotechnology, Inc. to provide qualified Acentrus clients access to NERLYNX (neratinib), a breast cancer treatment.
Participation in Acentrus is open to hospital organizations of all sizes, types and affiliations. Limited distribution drugs like NERLYNX are highly sought after but can be difficult to obtain.